Arielle Radin

Arielle Radin

Auto-generated profile, based on publicly available information

Arielle Radin

Bruin Health Reading Massachusetts USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in Behaviour Research and Therapy
Verified
Journal Article
Open access
JBJulienne E. Bower
Julienne E. Bower
ARArielle Radin
Arielle Radin
KKKate Ryan Kuhlman
Kate Ryan Kuhlman
The brain and immune system are intricately connected, and perturbations in one system have direct effects on the other. This review focuses on these dynamic psychoneuroimmune interactions and their implications for mental and physical health in the context of the COVID-19 pandemic. In particular, we describe how psychological states influence antiviral immunity and the vaccine response, and how immune changes triggered by COVID (either via infection with SARS-CoV-2 or associated stressors) can influence the brain with effects on cognition, emotion, and behavior. We consider negative psychological states, which have been the primary focus of psychological research in the context of COVID-19 (and psychoneuroimmunology more generally). We also consider positive psychological states, including positive affect and eudaimonic well-being, given increasing evidence for their importance as modulators of immunity. We finish with a discussion of interventions that may be effective in improving immune function, the neuro-immune axis, and ultimately, mental and physical health.

6 May 2024 in Stress
Verified
Journal Article
Open access
RGRachel Gilgoff
Rachel Gilgoff
SMSummer Mengelkoch
Summer Mengelkoch
JEJorina Elbers
Jorina Elbers
KKKrista Kotz
Krista Kotz
ARArielle Radin
Arielle Radin
GSGeorge M. Slavich
George M. Slavich
Although dysregulated stress biology is becoming increasingly recognized as a key driver of lifelong disparities in chronic disease, we presently have no validated biomarkers of toxic stress physiology; no biological, behavioral, or cognitive treatments specifically focused on normalizing toxic stress processes; and no agreed-upon guidelines for treating stress in the clinic or evaluating the efficacy of interventions that seek to reduce toxic stress and improve human functioning. We address these critical issues by (a) systematically describing key systems and mechanisms that are dysregulated by stress; (b) summarizing indicators, biomarkers, and instruments for assessing stress response systems; and (c) highlighting therapeutic approaches that can be used to normalize stress-related biopsychosocial functioning. We also present a novel multidisciplinary Stress Phenotyping Framework that can bring stress researchers and clinicians one step closer to realizing the goal of using precision medicine-based approaches to prevent and treat stress-associated health problems.

6 October 2025 in Cancer
Verified
Journal Article
Open access
JBJulienne E. Bower
Julienne E. Bower
ARArielle Radin
Arielle Radin
PGPatricia A. Ganz
Patricia A. Ganz
MIMichael Irwin
Michael Irwin
SCSteve W. Cole
Steve W. Cole
CCCatherine M. Crespi
Catherine M. Crespi
Background: Fatigue is a common and long‐lasting side effect of cancer. Although fatigue is a multidimensional symptom, biologic mechanisms of fatigue dimensions have not been identified. Methods: Women recently diagnosed with early stage breast cancer ( n = 192) completed assessments before and after adjuvant therapy and at 6‐month, 12‐month, and 18‐month posttreatment follow‐up visits. At each assessment, women completed the Multidimensional Fatigue Symptom Inventory and provided blood for protein markers of inflammation (tumor necrosis factor [TNF] alpha [TNF‐α], soluble tumor necrosis factor receptor type II [sTNF‐RII], interleukin 6 [IL‐6], and C‐reactive protein [CRP]). Mixed‐effect linear models examined within‐person and between‐person associations between inflammatory markers and dimensions of fatigue. Results: Analyses demonstrated a positive within‐person association between general fatigue and TNF‐α ( b = 1.67; p = .037), sTNF‐RII ( b = 2.77; p = .002), and IL‐6 ( b = 0.86; p = .010) when controlling for age, race, education, body mass index, and cancer stage. Similarly, there was a positive within‐person association between physical fatigue and TNF‐α ( b = 1.58; p = .007), sTNF‐RII ( b = 2.38; p < .001), and CRP ( b = 0.43; p = .007). Conversely, there were negative within‐person associations between emotional fatigue and TNF‐α ( b = −1.92; p = .004) and sTNF‐RII ( b = −2.10; p = .006). General and physical fatigue were positively associated with CRP at the between‐person level ( b = 0.82, p = .024 for general; b = 0.71; p = .012 for physical). No significant associations between mental fatigue and inflammatory makers were found. Conclusions: The current findings identified distinct dimensions of fatigue associated with inflammatory activity in women with breast cancer and highlighted individual variability in inflammatory markers as a key predictor of fatigue symptoms.

1 April 2021 in Psychosomatic Medicine
Verified
Journal Article
Closed access
ARArielle Ma Radin
Arielle Ma Radin
PGPatricia A. Ganz
Patricia A. Ganz
KDKathleen Van Dyk
Kathleen Van Dyk
ASAnnette L. Stanton
Annette L. Stanton
JBJulienne E. Bower
Julienne E. Bower
Objective: Cognitive difficulties are a common complaint among patients with breast cancer and may adversely affect psychological well-being. In particular, problems with executive functioning (EF) may interfere with coping, which is known to influence depressive symptoms. The current study was designed to examine correlations between EF, coping, and depressive symptoms in breast cancer survivors and to longitudinally test the hypothesis that coping mediates the relationship between EF and depressive symptoms. Methods: Participants included 171 women with early-stage breast cancer assessed at the end of primary treatment with surgery, radiation, and/or chemotherapy and at 6 months, 1 year, and 2 years after treatment follow-ups as part of the Mind-Body Study. Participants completed questionnaires to assess subjective EF, approach and avoidant coping, and depressive symptoms, and neuropsychological testing was conducted to assess objective EF. Bivariate correlations were used to examine associations between EF, coping, and depressive symptoms. Mediation analyses were conducted using a bootstrapping approach (PROCESS). Results: At 1 year after treatment, objective and subjective EFs were correlated with avoidant coping (r = −0.172 [p = .024] and r = 0.297 [p < .001], respectively). In longitudinal analyses, use of the avoidant strategy behavioral disengagement at 1 year mediated the association between objective (95% bootstrap confidence interval = −0.282 to −0.042) and subjective (95% bootstrap confidence interval = 0.020 to 0.254) EFs at 6 months and depressive symptoms at 2 years. Conclusions: This study highlights how problems with EF during survivorship are associated with avoidant coping and depressive symptoms. Thus, these findings identify potential cognitive and affective targets for depression intervention in this population.

4 March 2021 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
ARArielle S. Radin
Arielle S. Radin
KKKate Ryan Kuhlman
Kate Ryan Kuhlman
CBChloe C. Boyle
Chloe C. Boyle
MHMarcie D. Haydon
Marcie D. Haydon
JBJulienne E. Bower
Julienne E. Bower
The influenza vaccine has shown promise as a mild, exogenous inflammatory challenge, but use of this model is limited by lack of knowledge about the timing of the inflammatory response. This study was designed to characterize the time-course of the acute inflammatory response and explore psychological and behavioral predictors of that response. Twenty-one young, healthy individuals were recruited to receive the annual influenza vaccine. Serial blood samples were collected immediately before, and 24, 48, and 72 ​h following influenza vaccination. Interleukin (IL)-6 concentrations were assayed at each time-point and psychological and behavioral factors (anxiety and depressive symptoms, sleep disturbance, and childhood adversity) were assessed at baseline. Significant elevations in IL-6 were observed at 24 ​h post-vaccination (mean increase ​= ​0.70 ​pg/mL, Cohen’s d ​= ​0.54, p ​= ​.018)), with 61.9% of participants exhibiting peak concentrations at that time point, χ 2 ​= ​22.54, p ​< ​.001, η ​= ​0.52. In exploratory analyses, sleep disturbance was associated with greater increases in IL-6 at 24 ​h. By identifying the peak IL-6 response to influenza vaccination among a sample of young, healthy individuals, these findings support the use of the influenza vaccine in future PNI research. This vaccine model can be used to examine the impact of mild inflammatory challenges on the brain and behavior, and to identify psychological and behavioral factors (e.g., anxiety, sleep) that modulate inflammatory reactivity.

8 August 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
ARArielle S. Radin
Arielle S. Radin
JBJulienne E. Bower
Julienne E. Bower
MIMichael R. Irwin
Michael R. Irwin
AAArash Asher
Arash Asher
Sara HurvitzSara Hurvitz
Sara Hurvitz
PGPatricia A. Ganz
Patricia A. Ganz
Contemporary breast cancer surgical procedures vary greatly by the amount of tissue removed, anesthesia time, and reconstruction. Despite historical literature comparing the health-related quality of life (HRQOL) after lumpectomy and mastectomy, HRQOL data are limited regarding contemporary surgical procedures. Further, biological processes (e.g., inflammation) associated with HRQOL outcomes have not been described. We conducted two studies to examine differences in post-operative physical and mental functioning, pain, fatigue, and systemic inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) in women with early-stage breast cancer. Study 1 assessed women before and after surgery (n = 27) and Study 2 used a large cross-sectional sample (n = 240) to confirm findings from Study 1 and included a no-surgery comparison group. In Study 1, women who received mastectomy had lower physical functioning than lumpectomy (ps < 0.05), and those who received bilateral mastectomy had worse pain (p < 0.01) and fatigue (p = 0.029) than lumpectomy. Results were replicated in Study 2: mastectomy groups exhibited poorer physical functioning (ps < 0.01) and greater pain (ps < 0.001) than lumpectomy, and bilateral mastectomy was associated with worse fatigue (p < 0.05). Women who received bilateral mastectomy had higher levels of CRP than lumpectomy (p < 0.01) and higher TNF-α than the no-surgery group (p < 0.05). All surgery groups exhibited higher IL-6 than no-surgery (ps < 0.05). More extensive surgery is associated with poorer postoperative HRQOL. As compared to lumpectomy and no-surgery, mastectomy is associated with higher concentrations of systemic inflammatory markers.